Is capmatinib currently included in medical insurance?

Capmatinib is a targeted therapy for patients with non-small cell lung cancer (NSCLC) with positive MET gene mutations. The drug has been successfully launched in China and has been included in the national medical insurance system. The launch of capmatinib provides a new treatment option for patients with positive MET gene mutations, especially when traditional treatments are not effective. The inclusion of medical insurance means that eligible patients can reimburse part of the expenses through medical insurance, reducing the cost of treatment.

Although capmatinib is already on the market in China and is included in medical insurance, due to its relatively short time on the market, patients in some areas may find it difficult to purchase the drug directly in local pharmacies. This may be related to the distribution channels and market supply of drugs. Patients may need to obtain them through hospitals or other channels when purchasing. In this case, patients can also choose to purchase the drug through overseas channels, especially some international drug sales platforms, although it may take some time and procedures.

In overseas markets, the original drug of capmatinib is relatively expensive. Taking the European and American markets as an example, the price of the original drug capmatinib is usually around tens of thousands of yuan, which is a considerable financial burden for many patients. However, with the introduction of generic drugs, patients can also choose more affordable generic drugs. Take the generic drug of capmatinib produced in Laos as an example. Its price is about more than 2,000 yuan, which is much cheaper than the original drug. The ingredients of the drug are basically the same as the original drug, and the effect and safety are relatively guaranteed.

In general, capmatinib has been included in the domestic medical insurance system and provides patients with new treatment options. Although domestic supply may present some challenges, patients can obtain medications through hospitals or overseas channels. Whether choosing original drugs or generic drugs, patients should make decisions based on the doctor's advice and their own financial situation during the treatment process.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib